FrancophonIA/ELRC3.0 huggingface dataset:
English: Effectiveness (no microbiological confirmation of diagnosis was performed) against non-bacteraemic pneumonia was also assessed.
Slovenian: Ocenjevali so tudi učinkovitost cepiva proti pljučnici brez bakteriemije, v primerih, ko diagnoza pljučnice ni bila mikrobiološko potrjena.
English: OUTER CARTON TEXT - 10 pre-filled syringes pack without needle: pack for multi pack presentation (5 x 10), without blue box
Slovenian: BESEDILO NA ŠKATLI - 10 napolnjenih injekcijskih brizg brez igle: pakiranje z več zavitki (5x10), brez Blue box-a
English: In parallel, there was a 62% reduction in vaccine type IPD in individuals over 5 years of age.
Slovenian: Podobno so se IPD, povzročene s serotipi, ki so vključeni v cepivo, pri osebah, starejših od 5 let, zmanjšale za 62 %.
English: LABEL TEXT - Outer wrapper label to be applied on the transparent foil for multi pack presentation (5 x 10), including the blue box
Slovenian: BESEDILO NA NALEPKI - nalepka zunanjega ovoja, ki bo nalepljena na prozorni foliji z več zavitki (5x10), vključno z blue box-om
English: A third dose is recommended in the second year of life.
Slovenian: Tretji odmerek je priporočljivo dati v drugem letu življenja.
English: Repeated dose subcutaneous toxicity studies (13 weeks, 7 injections of the clinical dose, one every other week, followed by a 4-week recovery period) of Prevenar in rats and monkeys revealed no evidence of any significant local or systemic toxic effects.
Slovenian: Študije subkutane toksičnosti ponavljajočih se odmerkov (13 tednov, 7 injekcij kliničnega odmerka, ena vsak drugi teden, temu je sledilo 4-tedensko obdobje okrevanja) cepiva Prevenar na podganah in opicah niso pokazale nikakršnih znakov pomembnih lokalnih ali sistemskih toksičnih učinkov.
English: Suspension for injection in pre-filled syringe.
Slovenian: suspenzija za injiciranje v napolnjeni injekcijski brizgi
English: When compared with no vaccination, point estimates for the effectiveness of 2-, 3-, or 4-doses given on an infant schedule were similar: 96% (95% CI 88-99); 95% (95% CI 88-99); and 100% (95% CI 94-100), respectively.
Slovenian: V primerjavi z necepljenjem so bile točkovne ocene za učinkovitost 2, 3 ali 4 odmerkov, danih po shemi za dojenčke, podobne: 96 % (95-odstotni interval zaupanja 88-99); 95 % (95-odstotni interval zaupanja 88-99); oziroma 100 % (95-odstotni interval zaupanja 94-100).
English: - If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please
Slovenian: - Če katerikoli neželeni učinek postane resen ali če opazite katerikoli neželeni učinek, ki ni omenjen v tem navodilu, obvestite svojega zdravnika ali farmacevta.
English: Different injectable vaccines should always be given at different injection sites.
Slovenian: Različna parenteralna cepiva se vedno dajejo na različna mesta.
English: The first dose may be given from the age of 2 months with a second dose at least 2 months later and a third (booster) dose at 11-15 months of age (see section 5.1)
Slovenian: Prvi odmerek se lahko da od starosti 2 mesecev naprej, drugega vsaj 2 meseca pozneje, tretji (poživitveni) odmerek pa v starosti 11-15 mesecev (glejte poglavje 5.1).
English: It is important to follow the instructions from the doctor, pharmacist, or nurse so that your child completes
Slovenian: Pomembno je, da upoštevate navodila zdravnika, farmacevta ali medicinske sestre, tako da otrok prejme vse predvidene odmerke cepiva v predvidenem času.
English: • Each injection will be given at least 1 month apart
Slovenian: • Vse nadaljnje odmerke bo prejel z vsaj enomesečnim presledkom med odmerki.
English: 1 or 10 pre- filled syringes with or without needle Multi pack of 5 packs of 10 pre-filled syringes without needle.
Slovenian: 1 ali 10 napolnjenih injekcijskih brizg z ali brez igle 5 setov s po 10 napolnjenimi injekcijskimi brizgami brez igel.
English: There are no data available to indicate whether the administration of 23-valent pneumococcal polysaccharide vaccine to unprimed children or to children primed with Prevenar might result in hyporesponsiveness to further doses of Prevenar.
Slovenian: Ni podatkov, ki bi kazali, ali uporaba 23-valentnega pnevmokoknega polisaharidnega cepiva pri otrocih, ki še niso bili cepljeni, ali pri otrocih, že cepljenih s cepivom Prevenar, lahko povzroči zmanjšano odzivnost na nadaljnje odmerke cepiva Prevenar.
English: Prevenar is given to children from 2 months to 5 years to help protect against diseases such as: meningitis, sepsis or bacteraemia (bacteria in blood stream), pneumonia and ear infection caused by seven types of the bacteria Streptococcus pneumoniae.
Slovenian: Cepivo Prevenar uporabljamo za cepljenje otrok, starih od 2 mesecev do 5 let, za zaščito pred boleznimi kot so: meningitis, sepsa ali bakteriemija (bakterije v krvi), pljučnica in okužbe ušesa, ki jih povzroča sedem tipov bakterije Streptococcus pneumoniae.
English: As many pathogens other than pneumococcal serotypes represented in the vaccine may contribute to the burden of pneumonia in children, protection against all clinical pneumonia is expected to be lower than for invasive pneumococcal disease.
Slovenian: Ker lahko k obremenitvi zaradi pljučnice pri otrocih prispevajo številni patogeni, ne samo pnevmokokni serotipi, ki so prisotni v cepivu, pričakujemo, da bo zaščita pred vsemi kliničnimi pljučnicami slabša kot zaščita pred invazivno pnevmokokno pljučnico.
English: When Prevenar is co-administered with hexavalent vaccines (DTaP/Hib(PRP-T)/IPV/HepB), the physician should be aware that data from clinical studies indicate that the rate of febrile reactions was higher compared to that occurring following the administration of hexavalent vaccines alone.
Slovenian: Če zdravnik kombinira cepivo Prevenar s šestvalentnim cepivom (DTaP/Hib(PRP-T)IPV/HepB), mora upoštevati, da se po podatkih iz kliničnih študij po kombiniranem cepljenju pogosteje pojavljajo vročinske reakcije kot po samem šestvalentnem cepivu.
English: The use of Prevenar should be determined on the basis of official recommendations taking into consideration the impact of invasive disease in different age groups as well as variability of serotype epidemiology in different geographical areas (see sections 4.4, 4.8 and 5.1).
Slovenian: Uporabo cepiva Prevenar določimo na osnovi uradnih priporočil, ki upoštevajo pomembnost invazivnih bolezni po starostnih skupinah kot tudi variabilnost različnih geografskih serotipov (glejte
English: As with any vaccine, Prevenar may not protect all individuals receiving the vaccine from pneumococcal disease.
Slovenian: Podobno kot druga cepiva tudi Prevenar ne zaščiti vseh cepljenih posameznikov pred boleznimi, ki jih povzročajo pnevmokoki.
English: 0.5 ml suspension for injection in vial (Type I glass) with a grey butyl rubber stopper.
Slovenian: 0,5 ml suspenzije za injiciranje v viali (steklo tipa I) s sivim butilnim gumijastim zamaškom.
English: • Hypersensitivity reaction, including swelling of the face and/or lips, difficulty in breathing, rash,
Slovenian: • preobčutljivostne/alergijske reakcije z otekanjem obraza in/ali ustnic, oteženo dihanje, izpuščaj,
English: The effectiveness of Prevenar against IPD (i.e. comprising the protection afforded by vaccination and from herd immunity due to reduced transmission of vaccine serotypes in the population) has been evaluated in national immunisation programmes that employ three-dose or two-dose infant series, each with booster doses.
Slovenian: Učinkovitost cepiva Prevenar proti invazivnim pnevmokoknim boleznim (IPD), ki jo sestavljata zaščita, ki jo nudi cepljenje, in kolektivna zaščita v populaciji zaradi zmanjšanega prenašanja serotipov, ki so vključeni v cepivo, so ovrednotili v nacionalnih programih cepljenja, v katerih so uporabljali zaporedje treh odmerkov ali zaporedje dveh odmerkov za dojenčke, vedno tudi s poživitvenimi odmerki.
English: Although some antibody response to diphtheria toxoid may occur, immunisation with this vaccine does not substitute for routine diphtheria immunisation.
Slovenian: Čeprav lahko po cepljenju s cepivom Prevenar pride do določenega imunskega odgovora na davični toksoid, to cepivo ne more nadomestiti običajnega cepljenja proti davici.
English: The first dose may be given from the age of 2 months with a second dose at least 2 months later and a third (booster) dose at 11-15 months of age.
Slovenian: Prvi odmerek se lahko da od starosti 2 mesecev naprej, drugega vsaj 2 meseca pozneje, tretji (poživitveni) odmerek pa v starosti 11-15 mesecev.
English: Limited data have demonstrated that Prevenar induces an acceptable immune response in infants with sickle cell disease with a safety profile similar to that observed in non-high-risk groups.
Slovenian: Obstaja nekaj podatkov, ki so pokazali, da Prevenar pri dojenčkih z anemijo srpastih celic sproži sprejemljiv imunski odziv s podobnim varnostnim profilom kot pri skupinah, pri katerih tveganje ni veliko.
English: Data on concomitant administration of Prevenar with Infanrix hexa (DTaP/Hib(PRP-T)/IPV/HepB vaccine) have shown no clinically relevant interference in the antibody response to each of the individual antigens when given as a 3 dose primary vaccination.
Slovenian: Podatki o sočasni uporabi cepiva Infanrix hexa (DTaP/Hib(PRP-T)/IPV/HepB) s cepivom Prevenar kažejo, da ne pride do klinično pomembnih sprememb v tvorbi protiteles proti posameznim antigenom, če ga uporabimo kot osnovno cepljenje s tremi odmerki.
English: The vaccine should be given by intramuscular injection.
Slovenian: Cepivo se daje intramuskularno.
English: Like all vaccines, Prevenar can cause side effects, although not everybody gets them.
Slovenian: Kot vsa druga cepiva ima lahko tudi cepivo Prevenar neželene učinke, ki pa se ne pojavijo pri vseh cepljenih osebah.
English: A higher rate of local reactions has been observed in children older than 24 months of age compared with infants.
Slovenian: Pri otrocih, starejših od 24 mesecev, so opažali večjo pogostnost lokalnih reakcij kot pri dojenčkih.
English: Scientific conclusions and grounds for variation to the terms of the marketing authorisations
Slovenian: Znanstveni zaključki in podlaga za spremembo pogojev dovoljenja za promet z zdravilom
English: The use of pneumococcal conjugate vaccine does not replace the use of 23-valent pneumococcal polysaccharide vaccines in children  24 months of age with conditions (such as sickle cell disease, asplenia, HIV infection, chronic illness or who are immunocompromised) placing them at higher risk for invasive disease due to Streptococcus pneumoniae.
Slovenian: Uporaba konjugiranega pnevmokoknega cepiva ne nadomesti uporabe 23-valentnega pnevmokoknega polisaharidnega cepiva pri otrocih, starih  24 mesecev z večjim tveganjem (kot so otroci z anemijo srpastih celic, asplenijo, okužbo s HIV, kroničnimi boleznimi ali drugače imunsko kompromitirani); pri njih kljub vsemu ostaja večje tveganje za invazivno okužbo z bakterijo Streptococcus pneumoniae.
English: - for children with seizure disorders or with a prior history of febrile seizures.
Slovenian: - pri otrocih s konvulzijami ali pri tistih, ki imajo v anamnezi vročinske krče.
English: As with other vaccines, the administration of Prevenar should be postponed in subjects suffering from acute, severe febrile illness.
Slovenian: Kot pri drugih cepljenjih je treba tudi cepljenje s cepivom Prevenar odložiti pri otrocih, ki imajo akutno hudo vročinsko bolezen.
English: It is estimated that Prevenar could prevent 6-13% of all
Slovenian: Ocenjujejo, da bi cepivo Prevenar lahko preprečilo 6 %-13 % vseh kliničnih izbruhov AOM.
English: Prevenar will not protect against other Streptococcus pneumoniae serotypes than those included in the vaccine nor other micro-organisms that cause invasive disease or otitis media.
Slovenian: Cepivo Prevenar ne ščiti pred okužbami z drugimi serotipi bakterije Streptococcus pneumoniae kot s tistimi, ki so vključeni v cepivo, niti pred okužbami z drugimi mikroorganizmi, ki povzročajo invazivne okužbe ali vnetje srednjega ušesa.
English: Children with impaired immune responsiveness, whether due to the use of immunosuppressive therapy, a genetic defect, HIV infection, or other causes, may have reduced antibody response to active immunisation.
Slovenian: Otroci z oslabljeno imunostjo zaradi uporabe imunosupresivnih zdravil, genetske motnje, okužbe s HIV ali drugih vzrokov imajo lahko slabši imunski odziv na aktivno imunizacijo.
English: Do not inject intravenously.
Slovenian: Ni za intravensko dajanje.
English: Read all of this leaflet carefully before your child receives this vaccine.
Slovenian: Preden vaš otrok dobi to cepivo natančno preberite to navodilo!
English: Children aged 12 to 23 months should receive two injections.
Slovenian: Otroci, stari od 12 do 23 mesecev, morajo prejeti dva odmerka cepiva.
English: As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following the administration of the vaccine.
Slovenian: Kot pri drugih parenteralnih cepivih je tudi pri cepljenju s cepivom Prevenar potrebno imeti na voljo ustrezno medicinsko oskrbo in nadzor za morebitno redko anafilaktično reakcijo po dajanju cepiva.
English: Prevenar can be administered simultaneously with other paediatric vaccines in accordance with the recommended immunisation schedules.
Slovenian: Cepljenje s cepivom Prevenar lahko kombiniramo z drugimi cepivi za otroke, skladno z veljavnim programom imunoprofilakse.
English: The most common side effects (these may occur with more than 1 in 10 doses of the vaccine) are:
Slovenian: Najpogostejši neželeni učinki (lahko se pojavijo pri več kot 1 od 10 odmerkov cepiva) so:
English: A repeated dose intramuscular toxicity study (13 weeks, 5 injections, one every three weeks) of pneumococcal conjugate vaccine in rabbits revealed no evidence of any significant local or systemic toxic effects.
Slovenian: V študiji intramuskularne toksičnosti z večkratnimi odmerki (13 tednov, 5 injekcij, ena na tri tedne) konjugiranega pnevmokoknega cepiva na kuncih se niso pokazali nobeni pomembni lokalni ali sistemski toksični učinki.
English: This vaccine should not be given to infants or children with thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injection unless the potential benefit clearly outweighs the risk of
Slovenian: S tem cepivom se ne sme cepiti dojenčkov ali otrok s trombocitopenijo ali kako drugo motnjo strjevanja krvi, pri kateri je intramuskularno dajanje kontraindicirano, razen v primerih, ko je korist cepljenja očitno večja od potencialnega tveganja.
English: In a post licensure study involving 115 children between 2-5 years of age, tenderness was reported in up to 39.1 % of children; in 15.7 % of children the tenderness interfered with limb movement.
Slovenian: V raziskavi, ki je bila opravljena po registraciji cepiva in je zajela 115 otrok, starih od 2 do 5 let, so občutljivost zabeležili pri do 39,1 % otrok, pri 15,7 % otrok pa je občutljivost ovirala gibanje uda.
English: Manufacturing Authorisation Holder responsible for batch release:
Slovenian: Imetnik dovoljenja za promet z zdravilom, odgovoren za sproščanje serije:
English: 0.5 ml suspension for injection in pre-filled syringe (Type I glass) with a plunger rod (polypropylene), a plunger stopper (latex free grey butyl rubber) and a protective-tip cap (latex free grey butyl rubber)
Slovenian: 0,5 ml suspenzije za injiciranje v napolnjeni injekcijski brizgi (steklo tipa I) z ročajem bata (poliprolipen), zamašeni z batom (siva butilna guma brez lateksa) in zaščitnim pokrovčkom konice
English: A third injection will be given in the second year of life.
Slovenian: Tretji odmerek prejmejo v drugem letu življenja.
English: The impact of the vaccine on total number of episodes of otitis media regardless of etiology was a 7 % reduction (95 % CI: 4, 10).
Slovenian: Cepivo je zmanjšalo celotno število izbruhov vnetja srednjega ušesa ne glede na etiologijo za 7 % (95-odstotni interval zaupanja: 4, 10).
English: VIAL LABEL
Slovenian: NAVODILO ZA UPORABO
English: In a post licensure study involving 115 children between 2-5 years of age, tenderness was reported in 39.1 % of children; in 15.7 % of children the tenderness interfered with limb movement.
Slovenian: V raziskavi, ki je bila opravljena po registraciji cepiva in je zajela 115 otrok, starih od 2 do 5 let, so občutljivost zabeležili pri 39,1 % otrok, pri 15,7 % otrok pa je občutljivost ovirala gibanje uda.
English: Children aged 2 to 5 years should receive one injection.
Slovenian: Otroci, stari od 2 do 5 let, morajo prejeti en odmerek cepiva.
English: The effectiveness of a two-dose primary series has not been established against pneumonia or acute otitis
Slovenian: Učinkovitosti primarnega zaporedja dveh odmerkov proti pljučnici in akutnemu vnetju srednjega
English: Safety and immunogenicity data are not yet available for children in other specific high-risk groups for invasive pneumococcal disease (e.g. children with another congenital or acquired splenic dysfunction, HIV-infected, malignancy, nephrotic syndrome).
Slovenian: Podatki o varnosti in imunogenosti tega cepiva pri otrocih v drugih posebnih skupinah z visokim tveganjem za invazivne pnevmokokne okužbe še niso na voljo (kot so: otroci z drugo prirojeno ali pridobljeno motnjo delovanja vranice, otroci z okužbo s HIV, otroci z malignomi, nefrotskim sindromom).
English: The impact of the vaccine on total number of episodes of otitis media regardless of etiology was a 6 % (95 % CI: -4, 16)
Slovenian: Cepivo je zmanjšalo celotno število izbruhov vnetja srednjega ušesa ne glede na etiologijo za 6 % (95-odstotni interval zaupanja: -4, 16).
English: A 33 % (95 % CI: -1, 80) increase in AOM due to serogroups not included in the vaccine was observed in immunised subjects.
Slovenian: Pri cepljenih otrocih so opazili 33 % porast (95-odstotni interval zaupanja: -1, 80) akutnega vnetja srednjega ušesa, povzročenega s serotipi, ki jih cepivo ni vsebovalo.
English: For CRM-based Hib conjugate vaccine, enhancement of antibody responses to Hib and diphtheria in the infant series was observed.
Slovenian: Po uporabi konjugiranega cepiva Hib-CRM so pri dojenčkih opazili povečano tvorbo protiteles proti bakteriji Hib in davici.
English: Each injection will be given at least 1 month apart.
Slovenian: Med obema odmerkoma mora miniti vsaj en mesec.
English: In this follow-up, vaccine efficacy for frequent OM (defined as at least 3 episodes within 6 months) was 18 % (95 % CI: 1, 32), for chronic otitis media with effusion, 50 % (95 % CI: 15, 71), and for tympanostomy tube placement,
Slovenian: Pri tem spremljanju je bila učinkovitost pri pogostem vnetju srednjega ušesa (ki je bilo definirano kot vsaj 3 izbruhi v 6 mesecih) 18 % (95-odstotni interval zaupanja: 1, 32), pri kroničnem vnetju srednjega ušesa z izcedkom 50 % (95-odstotni interval zaupanja: 15, 71), pri vstavljeni timpanični cevki pa 39 %
English: Consequently, Prevenar should cover between 54 % and 84 % of isolates from invasive pneumococcal disease (IPD) in European children less than 2 years of age.
Slovenian: Zato velja ocena, da naj bi pri evropskih otrocih, mlajših od 2 let, cepivo Prevenar pokrilo 54 % do 84 % izoliranih pnevmokokov, ki povzročajo invazivne pnevmokokne bolezni (IPD - invasive pneumococcal disease).
English: Whenever recommended, children at risk who are ≥ 24 months of age and already primed with Prevenar should receive 23-valent pneumococcal polysaccharide vaccine.
Slovenian: Otroci s povečanim tveganjem, stari  24 mesecev, ki so bili cepljeni s cepivom Prevenar, naj prejmejo 23-valentno pnevmokokno polisaharidno cepivo kadarkoli je to potrebno.
English: OUTER CARTON TEXT - 1 vial pack
Slovenian: BESEDILO NA ŠKATLI - pakiranje z 1 vialo
English: Please speak to your doctor, pharmacist, or nurse for more information.
Slovenian: Za več informacij se posvetujte s svojim zdravnikom, farmacevtom ali z medicinsko
English: Prevenar suspension for injection Pneumococcal saccharide conjugated vaccine, adsorbed
Slovenian: Prevenar suspenzija za injiciranje konjugirano pnevmokokno saharidno cepivo, adsorbirano
English: Infants aged 7 to 11 months should receive two injections.
Slovenian: Dojenčki, stari od 7 do 11 mesecev, morajo prejeti dva odmerka cepiva.
English: The vaccine is a suspension for injection and provided in a single-dose vial (0.5 ml).
Slovenian: Prevenar je cepivo v obliki suspenzije za injiciranje; v vsaki viali je en odmerek (0,5 ml).
English: No consistent increased local or systemic reactions within repeated doses were seen throughout the primary series or with the booster dose, the exceptions being a higher rate of transient tenderness (36.5 %) and tenderness that interfered with limb movement (18.5 %) were seen with the booster dose.
Slovenian: Izjemi sta večja pogostnost prehodne občutljivosti (36,5 %) in občutljivosti, ki ovira gibanje uda (18,5 %), opaženi po poživitvenem odmerku.
English: Rare side effects (these may occur with up to 1 in 1,000 doses of the vaccine) are:
Slovenian: Redki neželeni učinki (lahko se pojavijo pri največ 1 od 1.000 odmerkov cepiva) so:
English: CONDITIONS OF THE MARKETING AUTHORISATION
Slovenian: ŠTEVILKE DOVOLJENJ ZA PROMET
English: • Seizures (or fits), including those caused by a high temperature
Slovenian: • krči, vključno z vročinskimi krči
English: As with other vaccines, the administration of Prevenar should be postponed in subjects suffering from acute moderate or severe febrile illness.
Slovenian: Kot druga cepljenja tudi cepljenje s cepivom Prevenar odložimo v primeru zmernih ali hudih akutnih
English: Hypersensitivity reactions such as anaphylactic/anaphylactoid reactions including shock, angioneurotic oedema, bronchospasm, dyspnoea, face oedema.
Slovenian: limfadenopatija v predelu mesta injiciranja preobčutljivostne reakcije kot je anafilaktična/anafilaktoidna reakcija, vključno s šokom, angionevrotičnim edemom, bronhospazmom, oteženim
English: A total of 52 cases of invasive disease caused by vaccine serotypes had accumulated in a blinded followup period through April 20, 1999.
Slovenian: V obdobju slepega sledenja do 20. aprila 1999 so ugotovili 52 primerov IPD, ki so jih povzročili serotipi, vključeni v cepivo.
English: • Pain, tenderness, redness, swelling, or hardness at the injection site; fever of 38 °C or higher,
Slovenian: • bolečina, občutljivost, rdečina, oteklina ali zatrdlina na mestu injiciranja; zvišana telesna temperatura 38 °C ali višja, razdražljivost, jok, zaspanost, nemiren spanec
English: Longterm persistence of antibodies has not been investigated after administration of a primary series in infants plus booster or after administration of single priming doses to older children.
Slovenian: Dolgoročne prisotnosti protiteles po primarni shemi cepljenja, vključno s poživitvenim odmerkom dojenčkom ali po dajanju enega samega prvega odmerka cepiva starejšim otrokom niso raziskovali.
English: Pack sizes of 1 and 10 with or without needle.
Slovenian: Pakiranji s po 1 vialo in s po 10 vialami z ali brez igle.
English: Pfizer AB Tel: +46 (0)8 550 520 00
Slovenian: Tel: +46 (0)8 550 520 00
English: The estimate for vaccine efficacy against vaccine-serotype AOM, the primary endpoint of the trial, was 57 % (95 % CI: 44, 67) in the per-protocol analysis and 54 % (95 % CI: 41, 64) in the intent-to-treat analysis.
Slovenian: Ocena učinkovitosti cepljenja proti akutnemu vnetju srednjega ušesa, povzročenem s serotipi v cepivu, ki je bila glavno merilo učinkovitosti v študiji, je bila 57 % (95-odstotni interval zaupanja: 44, 67) v skupini otrok, ki so opravili vsa cepljenja skladno s protokolom cepljenja, in 54 % (95-odstotni interval zaupanja: 41, 64) v skupini otrok, ki naj bi jih cepili (intent-to-treat).
English: Do not administer Prevenar intravenously.
Slovenian: Cepiva Prevenar se ne sme dati intravensko.
English: • Flushing
Slovenian: Pfizer
English: In general, adverse reactions reported with overdose have also been reported with recommended single doses of Prevenar.
Slovenian: Na splošno velja, da se neželeni učinki po prevelikem odmerjanju ne razlikujejo od tistih, o katerih poročajo po priporočenih enkratnih odmerkih.